|
rs35897606
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.
|
27339598 |
2016 |
|
rs73084982
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.
|
27339598 |
2016 |
|
rs73132848
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.
|
27339598 |
2016 |
|
rs79709413
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients.
|
27339598 |
2016 |
|
rs2978048
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.
|
24503447 |
2014 |
|
rs7262634
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.
|
24503447 |
2014 |
|
rs16851720
|
|
C |
0.700 |
GeneticVariation |
GWASCAT |
In the combined cohort of 2342 HCV-infected patients, the SNPs rs16851720 (in the total sample) and rs4374383 (in patients who received blood transfusions) were associated with fibrosis progression (P(combined) = 8.9 × 10(-9) and 1.1 × 10(-9), respectively).
|
22841784 |
2012 |
|
rs2629751
|
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.
|
22841784 |
2012 |
|
rs9380516
|
|
T |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.
|
22841784 |
2012 |
|
rs1800562
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Prevalence of anti-HCV in post-screening participants with HFE p.C282Y homozygosity and chronic HCV infection in referred adults with HFE p.C282Y homozygosity in North America is similar to that of Control participants with HFE wt/wt and normal screening TS/SF.
|
31056361 |
2020 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Host DNA from all HCV positive patients and age- and sex-matched non-HCV-infected control individuals were analysed for IL28B single nucleotide polymorphism (SNP) (rs12979860 and rs8099917).
|
30865664 |
2019 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Genetic polymorphisms within the interferon λ (IFN-λ) chromosomal region, mainly rs12979860 of IFN-λ4 gene (IFNL4), are known as associated with spontaneous hepatitis C virus (HCV) resolution and sustained viral response to therapy with pegylated interferon- α and ribavirin.
|
30027841 |
2019 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The <i>IL28B</i> rs12979860 CT/TT genotypes (OR = 3.44, 95% CI [2.12-5.58], <i>p</i> < 0.001), bAt haplotype (OR = 2.02, 95% CI [1.04-3.91], <i>p</i> = 0.03), pre-treatment serum HCV RNA (logIU/mL; OR = 1.73, 95% CI [1.31-2.28], <i>p</i> < 0.001), advanced liver fibrosis (OR = 1.68, 95% CI [1.10-2.58], <i>p</i> = 0.02), and HCV genotype 1 (OR = 1.59, 95% CI [1.07-2.37], <i>p</i> = 0.02) independently predicted poor response.
|
31565578 |
2019 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The most significant positive factors affecting the SC HCV included IL-28B single nucleotide polymorphism (SNP) rs12979860 (CC) and SNP rs8099917 (TT) (OR 4.03, p<0.001) and (OR 3.14, p<0.002), female gender (OR 2.72, p<0.001), young age (OR 2.30, p<0.008), and past history of jaundice (OR 5.12, p<0.001).
|
31060998 |
2019 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Besides normal routine laboratory testing for HCV, patients' sera were evaluated also for retinol, retinol-binding protein 4 and the following SNPs: PNPLA3 (rs738409), TM6SF2 (rs58542926), MBOAT7 (rs641738), IL28B (rs12979860), TIMP-1 (rs4898), TIMP-2 (rs8179090), NF-kB promoter (rs28362491).
|
31826071 |
2019 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<b>Results:</b> While the rs12979860 IFNL3 T allele was found a good marker associated with HCV-outcome together with the rs111200466 TLR2 del variant, the rs10204525 PD-1.6 A allele was found to have an insignificant role in patients with HCV-related hepatic disorders.
|
30930876 |
2019 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Multivariate logistic regression analysis indicated that cholesterol, triglyceride, low-density lipoprotein, 25-hydroxyvitamin D, platelets, duration of hemodialysis, HCV subtypes, IFNL3 rs12979860 TT, IFNL3 rs8099917 GG, IFNL3 rs12980275 GG, and IFNL4 ss469415590 ΔG/ΔG genotypes were associated with OCI.
|
30821879 |
2019 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The results of treatment response showed that CC (major) genotype of IFNL3 (rs12979860) and TT (major) genotype of IFNL3 (rs8099917) are associated with the likelihood of achieving a higher sustained virological response (SVR), to combined daclatasvir and sofosbuvir therapy, in genotype 3-infected HCV patients, whereas the individuals with TT (minor) genotype of IFNL3 (rs12979860) and GG (minor) genotype of IFNL3 (rs8099917) are more susceptible to chronic HCV infection and treatment relapse, suggesting a role of IFNL3 (rs12979860) and (rs8099917) in the treatment outcome of combined daclatasvir and sofosbuvir therapy in chronic HCV genotype 3 infection.
|
30431653 |
2019 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<b>Introduction:</b> IFNL4 rs12979860 genotype CC is associated with increased ALT activity and liver stiffness in hepatitis C virus (HCV) genotype (G) 3 infection but not in G1.
|
31479286 |
2019 |
|
rs12979860
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Sensitivity analyses suggested the robustness of the results in this meta-analysis.Both IL28B rs12979860 CC and rs8099917 TT genotypes are protective factors for the development of HCC among patients with HBV or HCV infection.
|
31568008 |
2019 |
|
rs12980275
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Multivariate logistic regression analysis indicated that cholesterol, triglyceride, low-density lipoprotein, 25-hydroxyvitamin D, platelets, duration of hemodialysis, HCV subtypes, IFNL3 rs12979860 TT, IFNL3 rs8099917 GG, IFNL3 rs12980275 GG, and IFNL4 ss469415590 ΔG/ΔG genotypes were associated with OCI.
|
30821879 |
2019 |
|
rs2596542
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TT genotype at rs2596542 was a risk factor for the development of HCC in patients with HCV/HBV infection (OR = 1.248, 95% CI: 1.040-1.499, P = 0.017), particularly those with HCV infection (OR = 1.326, 95% CI: 1.101-1.599, P = 0.003) and Asians (OR = 1.273, 95% CI: 1.002-1.618, P = 0.048), or when the control group was patients with chronic hepatitis C (CHC) (OR = 1.506, 95% CI: 1.172-1.936, P = 0.001).
|
31419949 |
2019 |
|
rs2596542
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Taken together our study suggest that MICA rs2596542 SNP impacts HCV-induced HCC susceptibility suggesting that genetic variants in MICA are of clinical relevance to hepatocarcinogenesis by impacting host immune response in chronic HCV infection.
|
31471884 |
2019 |
|
rs368234815
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Strong linkage disequilibrium of IFNL4 rs12979860 with IFNL4 rs368234815, which is casually associated with HCV spontaneous and therapeutical eradication, at least partially explains favorable HCV outcomes attributed to major homozygosity in rs12979860.
|
30027841 |
2019 |
|
rs368234815
|
|
|
0.100 |
GeneticVariation |
BEFREE |
However, the genetic ability to generate IFN-λ4, determined by the presence of the rs368234815-ΔG allele, is the strongest predictor of impaired clearance of hepatitis C virus (HCV) infection in humans.
|
31241411 |
2019 |